B+
Bull case
30%
Probability
Target price
$540.00
+1.9% vs current
MEDP
MedpaceCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$503.00
-5.1% vs current
B-
Bear case
25%
Probability
Target price
$395.00
-25.5% vs current
AI sentiment snapshot
Latest data as of 2026-06-18
Recent news sentiment (30D)
+0.2
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+36.7
Score
AI commentary
Primary-source evidence is strong, but the setup still reads as a monitoring-style positive rather than a clean momentum call. News flow over the last 30 days has been dominated by the Q1 release, the June leadership update, and the announced July 22 Q2 report date. The stock's $457.09 anchor sits above the post-earnings weakness referenced in secondary coverage, suggesting some recovery, but the market still appears to want proof that awards and margins can both hold into Q2. Analyst revision detail is not available in the packet, which lowers conviction somewhat despite solid company-reported fundamentals.
RankAlpha Sentiment Codex - 2026-06-18
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-07-22eventQ2 2026 print will test awards momentum and book-to-bill recoveryHigh impact
Medpace is scheduled to report Q2 2026 results on 2026-07-22; the key check is whether Q1 revenue growth of 26.5% and net new awards growth of 23.7% can convert into a book-to-bill back above the Q1 level of 0.88x while management holds 2026 guidance [#SEC-8K-2026-04-22].
2026-09-30catalystOperations leadership transition needs clean executionMedium impact
Brad Hansman was appointed Executive Vice President, Operations effective 2026-06-01 and will share principal operating officer duties; his background spans study start-up, logistics, regulatory affairs, and medical writing, so investors will watch for continuity in trial execution and sponsor service levels [#8-K-2026-06-04].
2026-12-31catalystBacklog conversion, margin stability, and cash generation can support reratingHigh impact
Q1 backlog reached $2.93 billion, operating cash flow was $151.8 million, and full-year revenue guidance remains $2.755-$2.855 billion; if Medpace sustains conversion and protects EBITDA margin near the Q1 21.1% level, the market can re-rate the stock despite current caution around booking cadence [#SEC-8K-2026-04-22].
Recommendation
N/A
No formal recommendation provided.
As of 2026-06-18 • Updated nightlySource: Internal modelMethodology